Pomegra
Pathos AI closed a $237M Series E led by Bristol Myers Squibb at a roughly $3B valuation to push four clinical oncology assets and its Foundry AI platform.
Key Takeaways
- Pathos AI raised $237M in Series E funding at about a $3B post-money valuation, announced October 23, 2026.
- Bristol Myers Squibb led the round, with unnamed existing investors participating.
- The valuation is roughly 1.9x the $1.6B set in the May 2025 Series D.
Lead
Pathos AI, the New York oncology drug developer, announced a $237M Series E on October 23, 2026, at a post-money valuation of about $3B. Bristol Myers Squibb led the round, and existing investors took part. The company has not named them.
Pathos says the money will expand Foundry, its AI platform, and advance a pipeline of four clinical-stage cancer programs. Its stated priorities include moving the antibody-drug conjugate JSKN016 toward registrational studies. CEO Iker Huerga framed the aim as a platform that "systematically improves the probability of success in drug development."
What Does the Series E Say About the Series D?
The Series E nearly doubles the valuation set 17 months earlier. In May 2025, Pathos raised $365M in a Series D at about $1.6B, bringing its total to roughly $467M at that point. Adding the $237M puts cumulative funding across the Series C, D and E at about $664M, based on the $62M Series C reported before the Series D.
The round is smaller than the Series D by about $128M, yet it priced higher. That points to investors paying for clinical progress rather than for the AI pitch alone. When the Series D closed, Pathos listed two clinical assets: pocenbrodib and P-500. The current four-asset list names pocenbrodib, JSKN016, AZD4241 and DO-2.
Pathos has not disclosed the share of the company sold in the round. It has also not said how much of the $237M came from Bristol Myers Squibb versus existing backers.
What Is Pathos Building With Foundry?
Foundry is a proprietary platform that runs thousands of specialized AI agents. They continuously pull in clinical data, genomics, biological specimen data and shifts in the competitive field. The company says the system helps decide a program's next step, identify patient subpopulations likely to respond, and cut high-risk projects early.
The approach is a portfolio filter. Pathos in-licenses or partners on assets, then uses Foundry to decide where to spend. The company points to its four clinical programs as evidence the filter works, though none has reported pivotal data.
Which Assets Does the Money Fund?
The pipeline spans four programs across solid tumors and blood cancers:
- Pocenbrodib, a CREBBP/EP300 inhibitor licensed from Novo Nordisk in 2023, in metastatic castration-resistant prostate cancer and relapsed or refractory multiple myeloma.
- JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate for solid tumors expressing both targets.
- AZD4241, an estrogen receptor PROTAC developed with AstraZeneca for ER-positive, HER2-negative breast cancer.
- DO-2, a next-generation MET kinase inhibitor for MET-altered non-small-cell lung cancer.
Registrational studies are the expensive step. Moving JSKN016 into one will likely absorb a large share of the round, although Pathos has not published an allocation.
Why Does Bristol Myers Squibb Leading Matter?
A large pharmaceutical company leading a private round signals strategic interest rather than a purely financial bet. Bristol Myers Squibb already has a collaboration with Pathos on Alzheimer's disease and other neurological conditions. Huerga has said the 99% failure rate in neurological trials cannot be fixed with incremental changes.
The oncology round gives Bristol Myers Squibb a closer view of Foundry's decision-making. Pathos's other corporate ties run deep. AstraZeneca and Tempus AI were corporate investors in the Series D, and Pathos was founded by executives from Tempus. Huerga came from AstraZeneca, where he was chief data scientist for oncology R&D. Pathos has not disclosed the terms of any Bristol Myers Squibb rights tied to the Series E.
What Comes Next for Pathos?
The next test is clinical rather than computational. JSKN016 entering a registrational study would be the first sign that Foundry-selected assets can reach late-stage development. Data readouts for pocenbrodib in prostate cancer and multiple myeloma would add a second read on asset selection.
A $3B valuation also sets a bar for the next financing or a public listing. An IPO or sale would need late-stage evidence, not platform claims. The AI drug-discovery sector has seen many platform-led companies struggle once their assets reached mid-stage trials, so investors will likely weigh Pathos against that record. A partner round with Bristol Myers Squibb or AstraZeneca is a plausible alternative path.
Outlook
Pathos AI has roughly doubled its valuation in 17 months on a smaller round, with a pharma giant now leading. Its four clinical assets and the Foundry platform now carry the case. Registrational progress on JSKN016 and early data from pocenbrodib will show whether the premium holds.
